- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
The RNA Interference (RNAi) Drug Delivery market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global RNA Interference (RNAi) Drug Delivery market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Infectious Diseases accounting for % of the RNA Interference (RNAi) Drug Delivery global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Nanoparticle Drug Delivery Technology segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of RNA Interference (RNAi) Drug Delivery include Metabolic disorders, Alnylam Pharmaceuticals Inc, Merck & Co. Inc, Access Pharmaceuticals Inc, and Dicerna Pharmaceuticals Inc, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
RNA Interference (RNAi) Drug Delivery market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Nanoparticle Drug Delivery Technology
Pulmonary Drug Delivery Technology
Nucleic Acid Drug Delivery Technology
Aptamer Drug Delivery Technology
Market segment by Application can be divided into
Infectious Diseases
Cardiology
Oncology
Neurology
Ophthalmology
Metabolic Disorders
The key market players for global RNA Interference (RNAi) Drug Delivery market are listed below:
Metabolic disorders
Alnylam Pharmaceuticals Inc
Merck & Co. Inc
Access Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Calondo Pharmaceuticals Inc
Marina Biotech Inc
RXi Pharmaceuticals Corp
Quark Pharmaceuticals Inc
Silence Therapeutics plc
Tacere Therapeutics Inc
PhaseRx Inc
Sirnaomics Inc
Traversa Therapeutics Inc
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe RNA Interference (RNAi) Drug Delivery product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of RNA Interference (RNAi) Drug Delivery, with price, sales, revenue and global market share of RNA Interference (RNAi) Drug Delivery from 2019 to 2022.
Chapter 3, the RNA Interference (RNAi) Drug Delivery competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the RNA Interference (RNAi) Drug Delivery breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and RNA Interference (RNAi) Drug Delivery market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of RNA Interference (RNAi) Drug Delivery.
Chapter 13, 14, and 15, to describe RNA Interference (RNAi) Drug Delivery sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 RNA Interference (RNAi) Drug Delivery Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global RNA Interference (RNAi) Drug Delivery Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Nanoparticle Drug Delivery Technology
1.2.3 Pulmonary Drug Delivery Technology
1.2.4 Nucleic Acid Drug Delivery Technology
1.2.5 Aptamer Drug Delivery Technology
1.3 Market Analysis by Application
1.3.1 Overview: Global RNA Interference (RNAi) Drug Delivery Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Infectious Diseases
1.3.3 Cardiology
1.3.4 Oncology
1.3.5 Neurology
1.3.6 Ophthalmology
1.3.7 Metabolic Disorders
1.4 Global RNA Interference (RNAi) Drug Delivery Market Size & Forecast
1.4.1 Global RNA Interference (RNAi) Drug Delivery Sales in Value (2017 & 2021 & 2028)
1.4.2 Global RNA Interference (RNAi) Drug Delivery Sales in Volume (2017-2028)
1.4.3 Global RNA Interference (RNAi) Drug Delivery Price (2017-2028)
1.5 Global RNA Interference (RNAi) Drug Delivery Production Capacity Analysis
1.5.1 Global RNA Interference (RNAi) Drug Delivery Total Production Capacity (2017-2028)
1.5.2 Global RNA Interference (RNAi) Drug Delivery Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 RNA Interference (RNAi) Drug Delivery Market Drivers
1.6.2 RNA Interference (RNAi) Drug Delivery Market Restraints
1.6.3 RNA Interference (RNAi) Drug Delivery Trends Analysis
2 Manufacturers Profiles
2.1 Metabolic disorders
2.1.1 Metabolic disorders Details
2.1.2 Metabolic disorders Major Business
2.1.3 Metabolic disorders RNA Interference (RNAi) Drug Delivery Product and Services
2.1.4 Metabolic disorders RNA Interference (RNAi) Drug Delivery Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Alnylam Pharmaceuticals Inc
2.2.1 Alnylam Pharmaceuticals Inc Details
2.2.2 Alnylam Pharmaceuticals Inc Major Business
2.2.3 Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product and Services
2.2.4 Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Merck & Co. Inc
2.3.1 Merck & Co. Inc Details
2.3.2 Merck & Co. Inc Major Business
2.3.3 Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Product and Services
2.3.4 Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Access Pharmaceuticals Inc
2.4.1 Access Pharmaceuticals Inc Details
2.4.2 Access Pharmaceuticals Inc Major Business
2.4.3 Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product and Services
2.4.4 Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Dicerna Pharmaceuticals Inc
2.5.1 Dicerna Pharmaceuticals Inc Details
2.5.2 Dicerna Pharmaceuticals Inc Major Business
2.5.3 Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product and Services
2.5.4 Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Calondo Pharmaceuticals Inc
2.6.1 Calondo Pharmaceuticals Inc Details
2.6.2 Calondo Pharmaceuticals Inc Major Business
2.6.3 Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product and Services
2.6.4 Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Marina Biotech Inc
2.7.1 Marina Biotech Inc Details
2.7.2 Marina Biotech Inc Major Business
2.7.3 Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Product and Services
2.7.4 Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 RXi Pharmaceuticals Corp
2.8.1 RXi Pharmaceuticals Corp Details
2.8.2 RXi Pharmaceuticals Corp Major Business
2.8.3 RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Product and Services
2.8.4 RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Quark Pharmaceuticals Inc
2.9.1 Quark Pharmaceuticals Inc Details
2.9.2 Quark Pharmaceuticals Inc Major Business
2.9.3 Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product and Services
2.9.4 Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Silence Therapeutics plc
2.10.1 Silence Therapeutics plc Details
2.10.2 Silence Therapeutics plc Major Business
2.10.3 Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Product and Services
2.10.4 Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Tacere Therapeutics Inc
2.11.1 Tacere Therapeutics Inc Details
2.11.2 Tacere Therapeutics Inc Major Business
2.11.3 Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Product and Services
2.11.4 Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 PhaseRx Inc
2.12.1 PhaseRx Inc Details
2.12.2 PhaseRx Inc Major Business
2.12.3 PhaseRx Inc RNA Interference (RNAi) Drug Delivery Product and Services
2.12.4 PhaseRx Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Sirnaomics Inc
2.13.1 Sirnaomics Inc Details
2.13.2 Sirnaomics Inc Major Business
2.13.3 Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Product and Services
2.13.4 Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 Traversa Therapeutics Inc
2.14.1 Traversa Therapeutics Inc Details
2.14.2 Traversa Therapeutics Inc Major Business
2.14.3 Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Product and Services
2.14.4 Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 RNA Interference (RNAi) Drug Delivery Breakdown Data by Manufacturer
3.1 Global RNA Interference (RNAi) Drug Delivery Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global RNA Interference (RNAi) Drug Delivery Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in RNA Interference (RNAi) Drug Delivery
3.4 Market Concentration Rate
3.4.1 Top 3 RNA Interference (RNAi) Drug Delivery Manufacturer Market Share in 2021
3.4.2 Top 6 RNA Interference (RNAi) Drug Delivery Manufacturer Market Share in 2021
3.5 Global RNA Interference (RNAi) Drug Delivery Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and RNA Interference (RNAi) Drug Delivery Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global RNA Interference (RNAi) Drug Delivery Market Size by Region
4.1.1 Global RNA Interference (RNAi) Drug Delivery Sales in Volume by Region (2017-2028)
4.1.2 Global RNA Interference (RNAi) Drug Delivery Revenue by Region (2017-2028)
4.2 North America RNA Interference (RNAi) Drug Delivery Revenue (2017-2028)
4.3 Europe RNA Interference (RNAi) Drug Delivery Revenue (2017-2028)
4.4 Asia-Pacific RNA Interference (RNAi) Drug Delivery Revenue (2017-2028)
4.5 South America RNA Interference (RNAi) Drug Delivery Revenue (2017-2028)
4.6 Middle East and Africa RNA Interference (RNAi) Drug Delivery Revenue (2017-2028)
5 Market Segment by Type
5.1 Global RNA Interference (RNAi) Drug Delivery Sales in Volume by Type (2017-2028)
5.2 Global RNA Interference (RNAi) Drug Delivery Revenue by Type (2017-2028)
5.3 Global RNA Interference (RNAi) Drug Delivery Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global RNA Interference (RNAi) Drug Delivery Sales in Volume by Application (2017-2028)
6.2 Global RNA Interference (RNAi) Drug Delivery Revenue by Application (2017-2028)
6.3 Global RNA Interference (RNAi) Drug Delivery Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America RNA Interference (RNAi) Drug Delivery Sales by Type (2017-2028)
7.2 North America RNA Interference (RNAi) Drug Delivery Sales by Application (2017-2028)
7.3 North America RNA Interference (RNAi) Drug Delivery Market Size by Country
7.3.1 North America RNA Interference (RNAi) Drug Delivery Sales in Volume by Country (2017-2028)
7.3.2 North America RNA Interference (RNAi) Drug Delivery Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe RNA Interference (RNAi) Drug Delivery Sales by Type (2017-2028)
8.2 Europe RNA Interference (RNAi) Drug Delivery Sales by Application (2017-2028)
8.3 Europe RNA Interference (RNAi) Drug Delivery Market Size by Country
8.3.1 Europe RNA Interference (RNAi) Drug Delivery Sales in Volume by Country (2017-2028)
8.3.2 Europe RNA Interference (RNAi) Drug Delivery Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales by Type (2017-2028)
9.2 Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales by Application (2017-2028)
9.3 Asia-Pacific RNA Interference (RNAi) Drug Delivery Market Size by Region
9.3.1 Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific RNA Interference (RNAi) Drug Delivery Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America RNA Interference (RNAi) Drug Delivery Sales by Type (2017-2028)
10.2 South America RNA Interference (RNAi) Drug Delivery Sales by Application (2017-2028)
10.3 South America RNA Interference (RNAi) Drug Delivery Market Size by Country
10.3.1 South America RNA Interference (RNAi) Drug Delivery Sales in Volume by Country (2017-2028)
10.3.2 South America RNA Interference (RNAi) Drug Delivery Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales by Type (2017-2028)
11.2 Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales by Application (2017-2028)
11.3 Middle East & Africa RNA Interference (RNAi) Drug Delivery Market Size by Country
11.3.1 Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa RNA Interference (RNAi) Drug Delivery Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of RNA Interference (RNAi) Drug Delivery and Key Manufacturers
12.2 Manufacturing Costs Percentage of RNA Interference (RNAi) Drug Delivery
12.3 RNA Interference (RNAi) Drug Delivery Production Process
12.4 RNA Interference (RNAi) Drug Delivery Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 RNA Interference (RNAi) Drug Delivery Typical Distributors
13.3 RNA Interference (RNAi) Drug Delivery Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
List of Tables
Table 1. Global RNA Interference (RNAi) Drug Delivery Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global RNA Interference (RNAi) Drug Delivery Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Metabolic disorders Basic Information, Manufacturing Base and Competitors
Table 4. Metabolic disorders Major Business
Table 5. Metabolic disorders RNA Interference (RNAi) Drug Delivery Product and Services
Table 6. Metabolic disorders RNA Interference (RNAi) Drug Delivery Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Alnylam Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 8. Alnylam Pharmaceuticals Inc Major Business
Table 9. Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product and Services
Table 10. Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Merck & Co. Inc Basic Information, Manufacturing Base and Competitors
Table 12. Merck & Co. Inc Major Business
Table 13. Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Product and Services
Table 14. Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Access Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 16. Access Pharmaceuticals Inc Major Business
Table 17. Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product and Services
Table 18. Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Dicerna Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 20. Dicerna Pharmaceuticals Inc Major Business
Table 21. Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product and Services
Table 22. Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Calondo Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 24. Calondo Pharmaceuticals Inc Major Business
Table 25. Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product and Services
Table 26. Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Marina Biotech Inc Basic Information, Manufacturing Base and Competitors
Table 28. Marina Biotech Inc Major Business
Table 29. Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Product and Services
Table 30. Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. RXi Pharmaceuticals Corp Basic Information, Manufacturing Base and Competitors
Table 32. RXi Pharmaceuticals Corp Major Business
Table 33. RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Product and Services
Table 34. RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Quark Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 36. Quark Pharmaceuticals Inc Major Business
Table 37. Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product and Services
Table 38. Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Silence Therapeutics plc Basic Information, Manufacturing Base and Competitors
Table 40. Silence Therapeutics plc Major Business
Table 41. Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Product and Services
Table 42. Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Tacere Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table 44. Tacere Therapeutics Inc Major Business
Table 45. Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Product and Services
Table 46. Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. PhaseRx Inc Basic Information, Manufacturing Base and Competitors
Table 48. PhaseRx Inc Major Business
Table 49. PhaseRx Inc RNA Interference (RNAi) Drug Delivery Product and Services
Table 50. PhaseRx Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Sirnaomics Inc Basic Information, Manufacturing Base and Competitors
Table 52. Sirnaomics Inc Major Business
Table 53. Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Product and Services
Table 54. Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 55. Traversa Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table 56. Traversa Therapeutics Inc Major Business
Table 57. Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Product and Services
Table 58. Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 59. Global RNA Interference (RNAi) Drug Delivery Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 60. Global RNA Interference (RNAi) Drug Delivery Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 61. Market Position of Manufacturers in RNA Interference (RNAi) Drug Delivery, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 62. Global RNA Interference (RNAi) Drug Delivery Production Capacity by Company, (K Units): 2020 VS 2021
Table 63. Head Office and RNA Interference (RNAi) Drug Delivery Production Site of Key Manufacturer
Table 64. RNA Interference (RNAi) Drug Delivery New Entrant and Capacity Expansion Plans
Table 65. RNA Interference (RNAi) Drug Delivery Mergers & Acquisitions in the Past Five Years
Table 66. Global RNA Interference (RNAi) Drug Delivery Sales by Region (2017-2022) & (K Units)
Table 67. Global RNA Interference (RNAi) Drug Delivery Sales by Region (2023-2028) & (K Units)
Table 68. Global RNA Interference (RNAi) Drug Delivery Revenue by Region (2017-2022) & (USD Million)
Table 69. Global RNA Interference (RNAi) Drug Delivery Revenue by Region (2023-2028) & (USD Million)
Table 70. Global RNA Interference (RNAi) Drug Delivery Sales by Type (2017-2022) & (K Units)
Table 71. Global RNA Interference (RNAi) Drug Delivery Sales by Type (2023-2028) & (K Units)
Table 72. Global RNA Interference (RNAi) Drug Delivery Revenue by Type (2017-2022) & (USD Million)
Table 73. Global RNA Interference (RNAi) Drug Delivery Revenue by Type (2023-2028) & (USD Million)
Table 74. Global RNA Interference (RNAi) Drug Delivery Price by Type (2017-2022) & (USD/Unit)
Table 75. Global RNA Interference (RNAi) Drug Delivery Price by Type (2023-2028) & (USD/Unit)
Table 76. Global RNA Interference (RNAi) Drug Delivery Sales by Application (2017-2022) & (K Units)
Table 77. Global RNA Interference (RNAi) Drug Delivery Sales by Application (2023-2028) & (K Units)
Table 78. Global RNA Interference (RNAi) Drug Delivery Revenue by Application (2017-2022) & (USD Million)
Table 79. Global RNA Interference (RNAi) Drug Delivery Revenue by Application (2023-2028) & (USD Million)
Table 80. Global RNA Interference (RNAi) Drug Delivery Price by Application (2017-2022) & (USD/Unit)
Table 81. Global RNA Interference (RNAi) Drug Delivery Price by Application (2023-2028) & (USD/Unit)
Table 82. North America RNA Interference (RNAi) Drug Delivery Sales by Country (2017-2022) & (K Units)
Table 83. North America RNA Interference (RNAi) Drug Delivery Sales by Country (2023-2028) & (K Units)
Table 84. North America RNA Interference (RNAi) Drug Delivery Revenue by Country (2017-2022) & (USD Million)
Table 85. North America RNA Interference (RNAi) Drug Delivery Revenue by Country (2023-2028) & (USD Million)
Table 86. North America RNA Interference (RNAi) Drug Delivery Sales by Type (2017-2022) & (K Units)
Table 87. North America RNA Interference (RNAi) Drug Delivery Sales by Type (2023-2028) & (K Units)
Table 88. North America RNA Interference (RNAi) Drug Delivery Sales by Application (2017-2022) & (K Units)
Table 89. North America RNA Interference (RNAi) Drug Delivery Sales by Application (2023-2028) & (K Units)
Table 90. Europe RNA Interference (RNAi) Drug Delivery Sales by Country (2017-2022) & (K Units)
Table 91. Europe RNA Interference (RNAi) Drug Delivery Sales by Country (2023-2028) & (K Units)
Table 92. Europe RNA Interference (RNAi) Drug Delivery Revenue by Country (2017-2022) & (USD Million)
Table 93. Europe RNA Interference (RNAi) Drug Delivery Revenue by Country (2023-2028) & (USD Million)
Table 94. Europe RNA Interference (RNAi) Drug Delivery Sales by Type (2017-2022) & (K Units)
Table 95. Europe RNA Interference (RNAi) Drug Delivery Sales by Type (2023-2028) & (K Units)
Table 96. Europe RNA Interference (RNAi) Drug Delivery Sales by Application (2017-2022) & (K Units)
Table 97. Europe RNA Interference (RNAi) Drug Delivery Sales by Application (2023-2028) & (K Units)
Table 98. Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales by Region (2017-2022) & (K Units)
Table 99. Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales by Region (2023-2028) & (K Units)
Table 100. Asia-Pacific RNA Interference (RNAi) Drug Delivery Revenue by Region (2017-2022) & (USD Million)
Table 101. Asia-Pacific RNA Interference (RNAi) Drug Delivery Revenue by Region (2023-2028) & (USD Million)
Table 102. Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales by Type (2017-2022) & (K Units)
Table 103. Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales by Type (2023-2028) & (K Units)
Table 104. Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales by Application (2017-2022) & (K Units)
Table 105. Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales by Application (2023-2028) & (K Units)
Table 106. South America RNA Interference (RNAi) Drug Delivery Sales by Country (2017-2022) & (K Units)
Table 107. South America RNA Interference (RNAi) Drug Delivery Sales by Country (2023-2028) & (K Units)
Table 108. South America RNA Interference (RNAi) Drug Delivery Revenue by Country (2017-2022) & (USD Million)
Table 109. South America RNA Interference (RNAi) Drug Delivery Revenue by Country (2023-2028) & (USD Million)
Table 110. South America RNA Interference (RNAi) Drug Delivery Sales by Type (2017-2022) & (K Units)
Table 111. South America RNA Interference (RNAi) Drug Delivery Sales by Type (2023-2028) & (K Units)
Table 112. South America RNA Interference (RNAi) Drug Delivery Sales by Application (2017-2022) & (K Units)
Table 113. South America RNA Interference (RNAi) Drug Delivery Sales by Application (2023-2028) & (K Units)
Table 114. Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales by Region (2017-2022) & (K Units)
Table 115. Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales by Region (2023-2028) & (K Units)
Table 116. Middle East & Africa RNA Interference (RNAi) Drug Delivery Revenue by Region (2017-2022) & (USD Million)
Table 117. Middle East & Africa RNA Interference (RNAi) Drug Delivery Revenue by Region (2023-2028) & (USD Million)
Table 118. Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales by Type (2017-2022) & (K Units)
Table 119. Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales by Type (2023-2028) & (K Units)
Table 120. Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales by Application (2017-2022) & (K Units)
Table 121. Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales by Application (2023-2028) & (K Units)
Table 122. RNA Interference (RNAi) Drug Delivery Raw Material
Table 123. Key Manufacturers of RNA Interference (RNAi) Drug Delivery Raw Materials
Table 124. Direct Channel Pros & Cons
Table 125. Indirect Channel Pros & Cons
Table 126. RNA Interference (RNAi) Drug Delivery Typical Distributors
Table 127. RNA Interference (RNAi) Drug Delivery Typical Customers
List of Figures
Figure 1. RNA Interference (RNAi) Drug Delivery Picture
Figure 2. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by Type in 2021
Figure 3. Nanoparticle Drug Delivery Technology
Figure 4. Pulmonary Drug Delivery Technology
Figure 5. Nucleic Acid Drug Delivery Technology
Figure 6. Aptamer Drug Delivery Technology
Figure 7. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by Application in 2021
Figure 8. Infectious Diseases
Figure 9. Cardiology
Figure 10. Oncology
Figure 11. Neurology
Figure 12. Ophthalmology
Figure 13. Metabolic Disorders
Figure 14. Global RNA Interference (RNAi) Drug Delivery Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 15. Global RNA Interference (RNAi) Drug Delivery Revenue and Forecast (2017-2028) & (USD Million)
Figure 16. Global RNA Interference (RNAi) Drug Delivery Sales (2017-2028) & (K Units)
Figure 17. Global RNA Interference (RNAi) Drug Delivery Price (2017-2028) & (USD/Unit)
Figure 18. Global RNA Interference (RNAi) Drug Delivery Production Capacity (2017-2028) & (K Units)
Figure 19. Global RNA Interference (RNAi) Drug Delivery Production Capacity by Geographic Region: 2022 VS 2028
Figure 20. RNA Interference (RNAi) Drug Delivery Market Drivers
Figure 21. RNA Interference (RNAi) Drug Delivery Market Restraints
Figure 22. RNA Interference (RNAi) Drug Delivery Market Trends
Figure 23. Global RNA Interference (RNAi) Drug Delivery Sales Market Share by Manufacturer in 2021
Figure 24. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by Manufacturer in 2021
Figure 25. RNA Interference (RNAi) Drug Delivery Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 26. Top 3 RNA Interference (RNAi) Drug Delivery Manufacturer (Revenue) Market Share in 2021
Figure 27. Top 6 RNA Interference (RNAi) Drug Delivery Manufacturer (Revenue) Market Share in 2021
Figure 28. Global RNA Interference (RNAi) Drug Delivery Sales Market Share by Region (2017-2028)
Figure 29. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by Region (2017-2028)
Figure 30. North America RNA Interference (RNAi) Drug Delivery Revenue (2017-2028) & (USD Million)
Figure 31. Europe RNA Interference (RNAi) Drug Delivery Revenue (2017-2028) & (USD Million)
Figure 32. Asia-Pacific RNA Interference (RNAi) Drug Delivery Revenue (2017-2028) & (USD Million)
Figure 33. South America RNA Interference (RNAi) Drug Delivery Revenue (2017-2028) & (USD Million)
Figure 34. Middle East & Africa RNA Interference (RNAi) Drug Delivery Revenue (2017-2028) & (USD Million)
Figure 35. Global RNA Interference (RNAi) Drug Delivery Sales Market Share by Type (2017-2028)
Figure 36. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by Type (2017-2028)
Figure 37. Global RNA Interference (RNAi) Drug Delivery Price by Type (2017-2028) & (USD/Unit)
Figure 38. Global RNA Interference (RNAi) Drug Delivery Sales Market Share by Application (2017-2028)
Figure 39. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by Application (2017-2028)
Figure 40. Global RNA Interference (RNAi) Drug Delivery Price by Application (2017-2028) & (USD/Unit)
Figure 41. North America RNA Interference (RNAi) Drug Delivery Sales Market Share by Type (2017-2028)
Figure 42. North America RNA Interference (RNAi) Drug Delivery Sales Market Share by Application (2017-2028)
Figure 43. North America RNA Interference (RNAi) Drug Delivery Sales Market Share by Country (2017-2028)
Figure 44. North America RNA Interference (RNAi) Drug Delivery Revenue Market Share by Country (2017-2028)
Figure 45. United States RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Canada RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Mexico RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Europe RNA Interference (RNAi) Drug Delivery Sales Market Share by Type (2017-2028)
Figure 49. Europe RNA Interference (RNAi) Drug Delivery Sales Market Share by Application (2017-2028)
Figure 50. Europe RNA Interference (RNAi) Drug Delivery Sales Market Share by Country (2017-2028)
Figure 51. Europe RNA Interference (RNAi) Drug Delivery Revenue Market Share by Country (2017-2028)
Figure 52. Germany RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. France RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. United Kingdom RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Russia RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Italy RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales Market Share by Region (2017-2028)
Figure 58. Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales Market Share by Application (2017-2028)
Figure 59. Asia-Pacific RNA Interference (RNAi) Drug Delivery Sales Market Share by Region (2017-2028)
Figure 60. Asia-Pacific RNA Interference (RNAi) Drug Delivery Revenue Market Share by Region (2017-2028)
Figure 61. China RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Japan RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Korea RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. India RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Southeast Asia RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Australia RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. South America RNA Interference (RNAi) Drug Delivery Sales Market Share by Type (2017-2028)
Figure 68. South America RNA Interference (RNAi) Drug Delivery Sales Market Share by Application (2017-2028)
Figure 69. South America RNA Interference (RNAi) Drug Delivery Sales Market Share by Country (2017-2028)
Figure 70. South America RNA Interference (RNAi) Drug Delivery Revenue Market Share by Country (2017-2028)
Figure 71. Brazil RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Argentina RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales Market Share by Type (2017-2028)
Figure 74. Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales Market Share by Application (2017-2028)
Figure 75. Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales Market Share by Region (2017-2028)
Figure 76. Middle East & Africa RNA Interference (RNAi) Drug Delivery Revenue Market Share by Region (2017-2028)
Figure 77. Turkey RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Egypt RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Saudi Arabia RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. South Africa RNA Interference (RNAi) Drug Delivery Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 81. Manufacturing Cost Structure Analysis of RNA Interference (RNAi) Drug Delivery in 2021
Figure 82. Manufacturing Process Analysis of RNA Interference (RNAi) Drug Delivery
Figure 83. RNA Interference (RNAi) Drug Delivery Industrial Chain
Figure 84. Sales Channel: Direct Channel vs Indirect Channel
Figure 85. Methodology
Figure 86. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
